reason report
pt
bottom line attend walgreen sell-sid analyst day
tuesday new york event unusu
includ buy-sid formal present rather
discuss overal sound ramp
data collect analysi effort longer term sound
want becom healthcar hub manag
pilot store commun florida flaunt new
model sound seek leverag lab audiolog
ophthalmolog dermatolog primari care servic
specif plan vagu time expect
increas number clinic network
next year compani alway interest
partnership valuat rel high
believ anyth immin longer term believ
seek acquir op though condit need
right deal happen also focus sell
higher margin front-of-stor product though may pressur
front-stor top-lin growth near term reduc pt
given current sentiment suppli chain on-going
reimburs headwind pressur intern divis
fewer near-term catalyst maintain mp rate
detail new store format elus manag highlight
deploy new store format commun florida
appear ambit becom healthcar hub howev
detail provid around result new store
see cost store invest exactli
chang locat sound ad audiolog
dermatolog ophthalmolog lab servic variou locat
number clinic expect remain stabl
next year greater focu healthcar hub
without expans presenc clinic urgent care center
unclear us truli transform way care
deliv local commun
long term estim acquisit candid
valuat high continu deliv strong bring
capit deploy question frequent manag describ
open activ current level
see mani opportun worth pursu return profil
substanti reduc high valuat
net debt total capit
price-to-earnings lt ep growth
ep
compani inform leerink partner llc research
ep exclud acquisition-rel cost acquisition-rel amort non-recur item includ lifo adjust revenu billion
pleas refer page import disclosur price chart analyst certif
substanti manag describ relationship
good continu believ addit valu
synergi achiev current relationship howev
estim manag continu see addit synergi
could achiev someth substanti current
relationship high valuat though manag view
viabl strategi current ultim believ
ceo steven colli would open deal eventu
believ compani come togeth
vertic integr achiev partnership other
pharma suppli chain continu consolid pursu vertic
integr ceo stefano pessina describ believ much
valu synergi afford vertic integr
achiev via partnership rather transact avoid capit
deploy requir merger describ actual
enhanc return profil vertic partnership rel merger
continu open work compani especi
improv volum store improv overal effici
cost system
updat guidanc manag provid updat
guidanc analyst day issu guidanc
fact forward look comment provid
manag attempt keep plan evolv
pharmaci close chest competit purpos expect
remain strong perform like driven
inorgan on-going integr store reduc
ep slightli pt move reimburs
headwind intern challeng slow retail volum
maintain mp
largest global pharmaci led retail pharmaceut wholesal organ
world walgreen us drugstor chain largest pharmaci chain us store count
industri size improv purchas power brand-nam recognit improv store traffic
overal volum health plan self-insur employ seek reduc medic cost via restrict
network believ walgreen in-stor clinic may provid attract altern plan
walgreen nation presenc also attract mani plan view provid larg corpor
broad access view gener launch wave next sever year posit impact
bottom line walgreen balanc reward custom loyalti program help lower print ad cost
bring individu market benefit recent work increas wba privat brand product share
mix well new front-end merchandis strategi posit impact same-stor sale profit
addit walgreen recent deal allianc boot offer promis long-
term synergi global growth back lost share esrx network
disput although grow accept narrow network remain risk walgreen
provid health plan wide array servic includ infus specialti dispens lab servic
hospit partnership primari care servic case walgreen also earli mover advantag
purchas jv boot deal walgreen pbm may advantag
case make retail chain payer agnost mani strength believ
retail channel face signific challeng includ increasingli competit environ
seek creat restrict prefer narrow network deal effort captur store
traffic volum medacorp specialist check indic retail rate reduc
case keep pressur retail gross margin
furthermor on-going gener launch believ wave larg behind
us becom increasingli difficult show gross margin expans retail also believ
transact posit busi stock howev deterior lose share
even though deal approv investor sentiment stock name appear low lastli
threat amazon enter pharmaci servic space continu weigh stock believ
retail exposur sinc own pbm given
risk concern rate share market perform
tuesday walgreen host sell-sid analyst day new york event featur comment
ceo stefano pessina cfo georg fairweath co-coo gourlay analyst day well
attend sell-sid analyst unusu prepar present buy-sid
attend day consist manag sell-sid discuss
provid opportun extract specif corpor strategi part discuss
high-level lengthi conceptu overal come away analyst day larg neutral
share see specif near- medium-term catalyst stock
data captur health servic seem
manag highlight learn work captur custom data
continu test pilot program select store unveil new store format base
work next twelv month unabl provid specif highlight compani
want becom hub healthcar deliveri commun deliv variou clinic servic
includ ophthalmolog hear dermatolog lower acuiti type servic digit technolog
solut use close align store pharmaci benefit
manag pbm health plan push sell higher margin sku store
health well orient
pilot creat gainesvil florida still somewhat unclear exact store layout
format go forward sound us increas number clinic
 though greater focu medic health servic unclear us
lab eye ear skin servic deploy greater extent throughout number
clinic remain howev seem commit new model lack clariti
somewhat disappoint us come away question answer
manag describ busi model base portfolio approach meant diversifi
compani across geographi busi unit manag open activ believ
necessari vertic integr achiev via partnership overli attract
current elev price specif disclos next stage manag
classifi three-stag journey appear seek evolv pharmaci hub
includ variou servic vari depend locat current oper clinic
experi ad addit servic audiolog dermatolog ophthalmolog lab
potenti urgent/primari care futur futur hub strategi sound interest
concern manag provid specif disappoint wait see
messag maintain market perform rate
past result sound forward vision unclear
view wba analyst day goal improv sell-sid sentiment perhap expens
provid action insight investor wba ceo stefano pessina began analyst day high-
level discuss busi model employ manag diversifi portfolio approach meant
diversifi compani geograph across busi unit comment transit past result
use support rational busi model discuss initi
work past sever year includ captur data custom neg
surpris lack data use year ago ceo pessina touch area
character concern compani includ stabil manag team gave high
level comment compani focu go forward manag reluct provid
specif blueprint path go forward even press respons one particularli
point question mr pessina respond oblig quit superfici answer view
tone taken manag deliv wait see messag manag describ within
next month roll chang point investor abl understand
compani head appreci need protect intern strateg initi
competit dynam market wait see modestli disappoint
manag track record sound good caution may warrant effect ask
investor trust manag next month believ caution warrant manag
quick highlight analyst day past three year end
deliv sale compound-annual-growth-rate grown adj ep annual period howev
note rel street compani perform mix past quarter
sale beat consensu estim time accord factset data averag
quarterli result comparison consensu estim ebitda result similarli
concern ebitda beat consensu time averag result rel consensu
howev ep period beat consensu time averag result exceed
consensu view wba earn perform partli driven consist string
signific adjust restructur charg mani charg valid view overal
qualiti earn decent best
adjust play substanti role perform adj ep recent year appar
previou chart adjust play larg role recent adj ep perform
adjust total total report adj ep adjust
report adj ep
quarterli surpris histori last yearsperiodev dateaft eventmeansurp eventmeansurp eventmeansurp jan oct jun apr jan oct jul apr jan oct jul apr dec sep jun dec oct jun ep previous held equiti decreas fair market valu releas capit loss valuat relat foreign currenc hedg boot equiti method non-cash relat restructur interest expens earli debt tax rate adj ep compani report leerink partner llc estim inc
wba journey three-part process busi model focus diversifi portfolio deliv
specif futur manag explain overal roadmap sinc merger
walgreen allianc boot three-part process
collect synergi origin walgreen allianc boot deal
extract valu model includ acquisit store
gener new busi model includ on-going concept test store pilot
manag describ action consist three-part journey
year compani continu second stage perform driven inorgan on-going
integr store throughout journey manag continu focu build
deliv portfolio approach diversifi geograph across mani busi unit
strategi ceo stefano pessina view chief invest offic work ensur return across
vari market environ dynam variou busi unit sourc synergi unit
third stage journey see creat healthcar hub
hub concept anchor pharmaci vari geographi though manag reluct give
mani specif futur plan detail teas help provid
outlook compani path forward describ greatest strength current role
commun pharmaci expect evolv time healthcar continu shift consum
driven model collect custom data analyz conjunct store
pilot test new store format payment model offer help evolv compani market
chang current oper clinic featur servic labcorp test audiolog
dermatolog ophthalmolog care howev current plan expand number
clinic us manag describ work focus evolv retail model
urgent care digit health present addit opportun manag view current
store footprint seen platform leverag provid addit servic
current offer clinic urgent care one area potenti growth compani tri
differ way deliv acut primari care manag describ activ view
separ current clinic model though view overal hub model sound could includ
wide array servic longer term manag current test sever thing pilot store
 attract appropri price
capit deploy question given strong gener histor gener
strong estim continu total gener total
estim gener given strong gener
capit deploy question manag describ open
mr pessina remark spent life ration gener
appropri return current manag view price elev result return would
singl digit suffici
note continu deliv strong gener compani approach trough level
base ltm price trade discount histor averag
factset
see addit synergi possibl current relationship though continu
believ may interest acquir alreadi manag
describ believ addit opportun work close drive
greater valu without pursu transact current relationship describ great
manag explain believ still synergi extract current
partnership comment suggest manag see compani evolv model
proactiv view market strength grow specialti space provid opportun
two compani work togeth creat addit valu
synergi possibl someth substanti member
pharma suppli chain vertic integr amid continu consolid
belief may seek acquir said past prefer partner compani
prior merger wba ownership conjunct two compani close work
togeth wbad drug purchas consortium make merger like view analyst day
manag discuss compani relationship suggest us fact
consid acquisit overal view price high present prevent
deal go manag describ interest deal lead singl
digit accret requir suffici roi engag complex process merg find
acquir remaind debt transact valu
adj ebitda estim impli total valu takeout stock price deal
would yield accret assum synergi accret would could
extract synergi believ would possibl
instead fund deal roughli stock debt assum purchas
price find deal would accret deal may appear make sens
current valuat believ deal would make sens longer term view wba interest
discuss potenti gain addit synergi posit price fall
attract level view appear may becom interest pursu someth
substanti unlock addit synergi
takeout sensit eev/ebitda takeout enterpris valu stock price stock compani document leerink partner llcwba ement debt deal eunown portion debt interest expens compani document leerink partner llcwba/ accret analysi debtrevenu gross tax ep share compani document leerink partner llc newcoaccret walgreen boot ianc inc
 seen necessari vertic integr face obviou question given continu
consolid vertic integr pharma suppli chain ceo stefano pessina explain
believ vertic integr think transact necessari vertic integr rather
believ mani benefit vertic integr deliv partner view
actual help deliv better return capit deploy potenti dilut effect
overpay anoth compani view base today high price believ partnership
attract rout gain effici synergi pursu possibl vertic deal
mind mr pessina describ open partnership especi drug price open
partner anyon help lower cost addit other pharma suppli chain pursu
vertic integr via merger manag describ see reason could partner
entiti
prefer regulatori transpar polici lower cost
consum
support increas transpar po rebat manag describ greatest
value-add discuss payer commun geograph proxim consum
store across countri offer payer abil touch member
conveni often lower-cost site care consum commun pharmacy-focus value-
proposit manag describ support legisl improv transpar
lower cost consum includ method shift rebat point sale po help
lower consum out-of-pocket cost interest grow concern govern view
good given on-going shift led trump administr tackl drug price reform
payment throughout pharma suppli chain
takeout sensit eev/ebitda takeout enterpris valu stock price stock compani document leerink partner llc debt stock deal dealnew debt interest expens stock stock compani document leerink partner llc/esrx accret analysi stock debtrevenu gross incom tax ep share compani document leerink partner llcaccret newco walgreen boot allianc inc
next month expect share trade ep would
put stock price multipl reflect on-going reimburs pressur minim
accret slowdown volum growth headwind intern busi
believ posit win share becom extens network vast array
clinic capabl believ new manag team take step reduc overal cost
increas sale higher margin front-stor product posit retail rate remain
signific pressur brand gener price also headwind becom aggress
overal respons market also overhang unlik abat time soon given
challeng concern rate share market perform
competit high retail pharmaci industri highli competit contract pbm
manufactur also competit walgreen compet chain independ drug store
well mail order prescript provid groceri store on-line pharmaci pharmaceut vendor
chang competit landscap impact rx volum neg impact compani sale
earn
macroeconom regulatori climat uncertainti continu econom slowdown
would bode poorli sinc above-averag unemploy rate drive lower level consum spend
would decreas prescript drug util regulatori environ also fair amount
uncertainti time impact variou healthcar reform provis could materi impact wba
oper nation emphasi reduc healthcar cost could also spawn reimburs pressur
new way contain healthcar cost devis implement
intern exposur execut risk walgreen merger allianc boot increas exposur
intern market increas currenc exposur regulatori risk wba partnership
uniqu approach contract distribut compani fail execut
vision accret could expect
season time cost adjust swing result front-end sale prescript
sale compon season sale also lumpi depend holiday line
calendar sever cold cough flu season magnitud compani lifo
provis also fluctuat given quarter depend inventori level sale inflat
also swing result contribut earn miss beat
potenti amazon entri amazon may seek disrupt pharmaci market enter retail
market buy build contract pbm news topic pose headlin risk
share amazon would formid competitor mail cash pay market
sale
revenu
revenu
gross profit sg spread bp
equiti earn ab
share allianc boot associ
sale acquisit adjust
revenu
revenu
net earn attr nci
revenu
total non-gaap adjust tax
incom statement model fiscal year end august mm
compani report leerink partner llc estim
revenu
revenu
equiti earn allianc boot
sale acquisit adjust
compani report leerink partner llc estim
revenu
revenu
revenu
revenu
adjust equiti earn
elimin unalloc
sale
incom statement model fiscal year end august mm
compani report leerink partner llc estim
incom statement model fiscal year end august mm
sale
equiti earn allianc boot
share allianc boot associ
previous held equiti interest
tax earn equiti method invest
net incom attrib non-control interest
net incom attrib walgreen
gain previous held equiti interest
increas decreas fair market valu warrant
partial releas capit loss valuat allow
loss sale busi
gain previous held equiti interest
increas decreas fair market valu warrant
partial releas capit loss valuat allow
compani report leerink partner llc estim
